Clinical Trial Update: Efficacy and Safety of JS002 as Monotherapy in Patients With Primary Hypercholesterolaemia and Mixed Dyslipidemia [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial is evaluating JS002 as monotherapy for primary hypercholesterolemia and mixed dyslipidemia. The study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypercholesterolemia
• Mixed Dyslipidemia

Drugs mentioned

• JS002

Snippet

Sponsor: Shanghai Junshi Bioscience Co., Ltd. | Conditions: Primary Hypercholesterolaemia and Mixed Dyslipidemia | Phase 3 | Status: RECRUITING